Olivier Barthélémy

Learn More
OBJECTIVES The aim of this study was to assess the association between the loss-of-function cytochrome P450 2C19 (CYP2C19)*2 variant (10 studies, 11,959 patients) or the use of proton pump inhibitors (PPIs) (13 studies, 48,674 patients) and ischemic outcomes (major adverse cardiovascular events [MACE]) in patients treated with clopidogrel. BACKGROUND In(More)
BACKGROUND Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy. METHODS We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platelet-function monitoring, with drug adjustment(More)
This thesis investigates the question of how new e-commerce technology is changing the organisational structure of value chains. The research presented in this thesis illustrates a new methodology that unites qualitative and quantitative approaches, by undertaking a detailed case study within a major international organisation. The focus is upon exploring(More)
OBJECTIVES This study sought to determine whether the pharmacokinetic (PK) and pharmacodynamic (PD) responses to high or standard clopidogrel loading doses (LDs) differ according to CYP2C19*2 allele. BACKGROUND CYP2C19 loss-of-function alleles are associated with reduced responsiveness to standard clopidogrel doses. METHODS Young post-myocardial(More)
Compared with the approved dose regimen of clopidogrel (300-mg loading dose [LD], 75-mg maintenance dose [MD]), prasugrel has been demonstrated to reduce ischaemic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In ACS, antiplatelet effects of a prasugrel MD regimen have not been previously compared(More)
BACKGROUND Optimum duration of dual antiplatelet treatment (DAPT) after coronary stenting remains uncertain, with an unknown efficacy to safety ratio of extended treatment leading to discrepancies between international guidelines and clinical practice. We assessed whether DAPT continuation beyond 1 year after coronary stenting is beneficial. METHODS This(More)
BACKGROUND Aldosterone, the final mediator of the renin-angiotensin-aldosterone pathway, is at its highest plasma levels at presentation for ST-elevation myocardial infarction (STEMI). Whether aldosterone level at presentation for STEMI is associated with adverse outcome remains unknown. METHODS AND RESULTS Plasma aldosterone levels were measured at(More)
A promising area of application for agent based social simulation is social policy analysis. This promise stems from the ability of ABSS models to describe key processes and relationships in actual societies. However, existing descriptive studies with ABSS have been too abstract convincingly to inform policy analysis. This paper describes the transition(More)
CONTEXT Despite dual antiplatelet therapy, stent thrombosis remains a devastating and unpredictable complication of percutaneous coronary intervention (PCI). OBJECTIVE To perform a sequential analysis of clinical and genetic factors associated with definite early stent thrombosis. DESIGN, SETTING, AND PARTICIPANTS Case-control study conducted in 10(More)
OBJECTIVES We sought to analyze the composition of coronary thrombus in vivo in ST-segment elevation myocardial infarction (STEMI) patients. BACKGROUND The dynamic process of intracoronary thrombus formation in STEMI patients is poorly understood. METHODS Intracoronary thrombi (n = 45) were obtained by thromboaspiration in 288 consecutive STEMI patients(More)